• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Switzerland·Financial Services·HBMN.SW
Share

HBM Healthcare Investments AG Stocks

CHF 251Last Updated 03.08.2026

Issuer Rating

5/7
Performance

Average

Risk

Low

Recommendation

Hold

Market Cap

CHF 2.05B

CHF 251
Key Takeaways

Risk factor

Low price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Solid dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

HBM Healthcare Investments AG specializes in both direct investments and a fund-of-funds strategy, focusing exclusively on the healthcare sector, encompassing human medicine, pharmaceuticals, biotechnology, diagnostics, and medical technology. Its direct investments target a diverse range of companies, from early-stage startups and various venture and growth phases to mature private enterprises, unlisted emerging firms, and small-cap public entities. The firm also provides capital for company buyouts, growth initiatives, Private Investments in Public Equity (PIPEs), and the spin-off of product lines or departments from larger corporations, as well as the expansion or restructuring of established businesses. Through its fund-of-funds approach, HBM allocates capital to venture capital funds. Initial direct investments are typically made in companies whose primary products are either in clinical development or just prior to that stage. With a global investment mandate, the company emphasizes opportunities in North America, Europe, and the Asia Pacific region. For publicly traded companies, HBM generally prioritizes those that originated within its private investment portfolio. The firm often increases its commitment to portfolio companies through subsequent financing rounds or after their initial public offering. HBM frequently secures a seat on the portfolio company's Board of Directors and may acquire majority stakes. While primarily investing through equity, it also employs various other financial instruments, including convertible bonds, debt securities, structured products, and derivatives. Exits from these investments are typically facilitated through trade sales or initial public offerings.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITDA, overpri

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Slightly negative
3/7

The average target price of HBMN.SW is 280 and suggests 11.6% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendat

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

07.09.2026 14:10

Tyra shares are having their best day in 10 months. Investors are awaiting new data on its drug

07.09.2026 13:11

U.S. inflation, Apple's latest products, Oracle's earnings report: What Investors Need to Know This Week

07.09.2026 12:22

Brent surged to $98. U.S. officials said the nuclear deal with Iran might not go through

07.09.2026 10:53

Top Stories This Morning: The U.S. Has Left Open the Possibility of Withdrawing from the Iran Nuclear Deal; Anthropic Has Postponed Its IPO

06.09.2026 21:00

Oura and Moonshot Have Filed for IPOs, Shein's Stock Plummets: What You Need to Know About IPOs by September 6

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026